Articles and Insights About Wearables for Clinical Trials

Neurology

Digital Measures of Physical Behavior for Alzheimer's Clinical Trials

 Shelby Bachman, PhD

In collaboration with researchers at the University of Massachusetts Amherst, VivoSense published a new review paper in the Journal of Alzheimer’s Disease. The review summarizes how measures of real-world physical behavior, captured with digital health technologies, can contribute to more holistic assessment of functional independence in Alzheimer’s disease clinical research.

Read More

The Importance of Patients as Partners in Alzheimer's Disease Research

 Jen Blankenship, PhD

Jen Blankenship, PhD, Senior Research Scientist, moderated a lively discussion with Shelby Bachman, PhD, Research Scientist, and an expert panel about the promise of Digital health technologies (DHTs) like smartphones and wearable sensors to advancing drug development and discovery in neurodegenerative diseases, particularly Alzheimer’s disease.

Read More

VivoSense Collaborates with Cambridge Cognition on the MEADOW-AD Study

 Kate Lyden, PhD

VivoSense is excited to announce a collaboration with Cambridge Cognition to capture measures of cognitive and physical function using digital health tools. Both organizations are united in their interests to develop low-burden and patient-centric digital clinical outcome measures that more comprehensively and holistically capture how individuals function in real-world environments.

Read More

VivoSense Joins the FNIH Biomarkers Consortium

 Dudley Tabakin

VivoSense announces that we have joined the Foundation for the National Institutes of Health’s (FNIH) Biomarkers Consortium! This new partnership strengthens our joint mission to facilitate the development of novel digital biomarkers using new and existing technologies, including evidence for their qualification in diagnostic medicine, therapeutic development, and clinical practice improvement.

Read More

VivoSense Study to Develop Digital Measures of Function for AD

 Jen Blankenship, PhD

At the a2 National Symposium: Empowering Innovation in AI/Tech + Aging, Senior Research Scientist Jen Blankenship, PhD, presented our ongoing work with the Center for Human Health and Performance at the University of Massachusetts Amherst to develop digital clinical measures that capture how patients with Alzheimer’s disease function in their real-world environments. 

Read More

VivoSense Awarded NIA/MassAITC Grant to Aid in Alzheimer's Research

 Dudley Tabakin

VivoSense, a trusted leader in the development, validation, and delivery of digital clinical measures, announced today that it has been awarded a research grant funded by the National Institute of Aging (NIA) and the Massachusetts Artificial Intelligence and Technology Center for Connected Care in Aging & Alzheimer’s Disease (MassAITC; grant number 5P30AG073107-02 Pilot A2).

Read More

Opportunities for Real-World Measures in Alzheimer's Research

 Jen Blankenship, PhD

Alzheimer’s disease (AD) is a devastating neurodegenerative disease that progresses to impact every dimension of a patient’s life. With no cure and limited options to manage symptoms, research is underway to develop drugs that impact the most burdensome aspects of AD: memory problems and the ability to function independently.

Read More

Understanding Neurodegenerative Diseases with Wearable Sensors

 Jen Blankenship, PhD

Millions of people across the globe struggle with neurodegenerative diseases every day. Neurodegenerative diseases are characterized by a breakdown of the central and peripheral nervous systems and cause progressive deterioration of a normally functioning human body. However, a significant challenge in studying neurodegenerative diseases is that direct measurements of neurological systems are invasive and expensive.

Wearable sensors can be used to understand disease progression and manifestation by measuring physical symptoms and physiological outcomes.

Read More
 Newer All Articles Older 

Stay Connected

Popular